# Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

> **NCT05807126** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Castration-Resistant Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Magrolimab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05807126
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-03-05
- **Primary completion:** 2026-12-06
- **Final completion:** 2026-12-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects enrolled in the study
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05807126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05807126, "Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05807126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*